ES2231667T3 - Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa. - Google Patents

Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa.

Info

Publication number
ES2231667T3
ES2231667T3 ES02701497T ES02701497T ES2231667T3 ES 2231667 T3 ES2231667 T3 ES 2231667T3 ES 02701497 T ES02701497 T ES 02701497T ES 02701497 T ES02701497 T ES 02701497T ES 2231667 T3 ES2231667 T3 ES 2231667T3
Authority
ES
Spain
Prior art keywords
alkyl
het
ethyl
optionally substituted
terminated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02701497T
Other languages
English (en)
Spanish (es)
Inventor
Stephen M. Pfizer Global R & D. Denton
Mark I. Pfizer Global R & D. Kemp
Sandra D. Pfizer Global R & D. Newman
David J. Pfizer Global R & D. Rawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2231667T3 publication Critical patent/ES2231667T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES02701497T 2001-03-16 2002-03-04 Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa. Expired - Lifetime ES2231667T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106661.2A GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds
GB0106661 2001-03-16

Publications (1)

Publication Number Publication Date
ES2231667T3 true ES2231667T3 (es) 2005-05-16

Family

ID=9910932

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02701497T Expired - Lifetime ES2231667T3 (es) 2001-03-16 2002-03-04 Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa.

Country Status (10)

Country Link
EP (1) EP1368352B1 (enExample)
JP (1) JP2004523585A (enExample)
AT (1) ATE283856T1 (enExample)
BR (1) BR0208154A (enExample)
CA (1) CA2439528A1 (enExample)
DE (1) DE60202134T2 (enExample)
ES (1) ES2231667T3 (enExample)
GB (1) GB0106661D0 (enExample)
MX (1) MXPA03005937A (enExample)
WO (1) WO2002074774A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
AU2004274403A1 (en) * 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006082001A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
BRPI0608381A2 (pt) * 2005-02-18 2009-12-29 Surface Logix Inc compostos aprimorados farmacocineticamente
AU2006315436A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
ATE464289T1 (de) * 2005-11-16 2010-04-15 Hoffmann La Roche Neues verfahren zur herstellung von thoc
US8071765B2 (en) * 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
TWI393578B (zh) 2009-07-07 2013-04-21 瑞健集團股份有限公司 注射裝置
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
TWI557121B (zh) 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN106029647A (zh) * 2013-12-20 2016-10-12 拜耳制药股份公司 葡萄糖转运抑制剂
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
KR102862562B1 (ko) 2015-11-16 2025-09-19 토파두르 파마 아게 포스포디에스테라제 억제제로서 2-페닐-3,4-디하이드로피롤로[2,1-f][1,2,4]트리아지논 유도체 및 이의 용도
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
HK1049834A1 (zh) * 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物

Also Published As

Publication number Publication date
JP2004523585A (ja) 2004-08-05
ATE283856T1 (de) 2004-12-15
CA2439528A1 (en) 2002-09-26
GB0106661D0 (en) 2001-05-09
DE60202134D1 (en) 2005-01-05
MXPA03005937A (es) 2003-09-10
DE60202134T2 (de) 2005-11-24
EP1368352A1 (en) 2003-12-10
BR0208154A (pt) 2004-03-02
WO2002074774A1 (en) 2002-09-26
EP1368352B1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
US6770645B2 (en) Pharmaceutically active compounds
EP1368352B1 (en) Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors
ES2241994T3 (es) Compuestos pirazolo(4,3-d)pirimidinona como inhibidores de gmpc.
ES2232502T3 (es) Derivados de pirazolo(4,3-d)pirimidina.
ES2326119T3 (es) 5,7-diaminopirazolo(4,3-d)pirimidinas utiles en el tratamiento de la hipertension.
ES2351622T3 (es) 5,7-diaminopirazolo[4,3-d]pirimidinas con actividad inhibidora de la pde-5.
SK4562002A3 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
MXPA00009938A (es) Compuestos farmaceuticamente activos.
US6784185B2 (en) Pharmaceutically active compounds
RS20080118A (sr) Piridinaminosulfonil supstituisani benzamidi kao inhibitori citohroma p450 3a4 (cyp3a4)
US6831074B2 (en) Pharmaceutically active compounds
EP1395589A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
US6794387B2 (en) Pharmaceutically active compounds
JP2002322180A (ja) 薬学的に活性な化合物
CA2585557C (en) Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
EP1380293A1 (en) Bone metabolism improving agents
JPWO2005042536A1 (ja) 複素環を有する新規縮合多環式化合物及びその医薬用途
HK1078574B (en) Pyrazolo [4,3-d] pyrimidine derivatives
HK1069577B (en) Pyrazolo [4,3-d] pyrimidine derivatives